The earnings result
Zimmer Biomet reported earnings on 2026-02-10 for the fiscal quarter ending Dec/2025. The calendar does not supply a complete reported-versus-consensus EPS comparison for this edition.
An EPS comparison describes one part of the release. Revenue, segment performance, cash conversion, guidance and the conference-call discussion require the original company disclosures; the result alone does not establish why the stock moved.
The market response
Price baseline: pre-report close. The baseline follows the reported announcement session.
The first measured session returned +1.86% from the stated baseline. The five-session return was +8.27%, and the 20-session return was +2.20%. SPY returned -2.42% across the corresponding window. Relative volume was 1.72 times the preceding 20-session average.
This edition is a source-based earnings-result and market-response analysis. A full financial-statement and conference-call dossier is not yet attached.